# Intravenous Ferric Carboxymaltose vs. Oral Iron Substitution in Patients With Metastatic Colorectal Cancer (CRC) and Iron Deficiency Anemia: a Randomized Multicenter Treatment Optimization Study.

> **NCT02469480** · PHASE2 · COMPLETED · sponsor: **Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest** · enrollment: 64 (actual)

## Conditions studied

- Metastatic Colorectal Cancer

## Interventions

- **DRUG:** FerInject
- **DRUG:** Ferro sanol

## Key facts

- **NCT ID:** NCT02469480
- **Lead sponsor:** Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-03
- **Primary completion:** 2020-05
- **Final completion:** 2020-08
- **Target enrollment:** 64 (ACTUAL)
- **Last updated:** 2020-10-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02469480

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02469480, "Intravenous Ferric Carboxymaltose vs. Oral Iron Substitution in Patients With Metastatic Colorectal Cancer (CRC) and Iron Deficiency Anemia: a Randomized Multicenter Treatment Optimization Study.". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02469480. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*